NCT04479644View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

February 3, 2021

Study Completion Date

February 3, 2021

Conditions
COVID-19
Interventions
DRUG

BRII-198

BRII-198 given intravenously

DRUG

Placebo

Placebo given intravenously

Trial Locations (1)

Unknown

Investigative Site, Beijing

Sponsors
All Listed Sponsors
collaborator

TSB Therapeutics (Beijing) CO.LTD

INDUSTRY

lead

Brii Biosciences Limited

INDUSTRY